title: Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors.
abstract: CD44 gene products are potential markers of aggressiveness in different tumour models, a result which prompted us to study clinical neuroblastoma (NB) specimens. CD44 expression was determined by immunostaining of 52 tumour samples from newly diagnosed NB with a monoclonal antibody (J173) directed against an epitope common to all CD44 isoforms. CD44 immunoreactivity was detected in 37 of the tumours (71%). CD44 was expressed in all 22 NBs with favourable prognoses (stages 1, 2 or 4S), but only 50% (15/30) of advanced NB (stages 3 and 4) (P < 10(-4)), suggesting that the absence, rather than the overexpression, of CD44 is a signal of tumour aggressiveness. The cumulative progression-free survival was significantly longer in patients with CD44 positive tumours compared with patients with CD44 negative tumours (P < 10(-5)). More importantly, progression-free survival was also significantly higher in CD44 positive patients within the high-risk group (P < 0.01). In univariate analysis, we tested the prognostic value of tumour expression of CD44 in comparison with tumour stage, age, tumour histology, and presence or absence of amplification of the MYCN protooncogene. All five measures had significant prognostic value. The expression of CD44 and the absence of MYCN amplification were the most powerful predictors of a favourable outcome. In a multivariate analysis of these measures, CD44 expression and tumour stage were the only independent prognostic factors for the prediction of patient survival. NB is the first clinical model described in which tumour aggressiveness correlates with repression rather than stimulation of CD44 expression. We recommend the use of CD44 as an additional biological marker in the initial staging of NB.
authors.affiliation: Hôpital Edouard Herriot, Lyon, France.
authors.forename: V
authors.initials: V
authors.lastname: Combaret
authors.forename: C
authors.initials: C
authors.lastname: Lasset
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.forename: R
authors.initials: R
authors.lastname: Bouvier
authors.forename: P
authors.initials: P
authors.lastname: Thiesse
authors.forename: A C
authors.initials: AC
authors.lastname: Rebillard
authors.forename: T
authors.initials: T
authors.lastname: Philip
authors.forename: M C
authors.initials: MC
authors.lastname: Favrot
mesh_terms: D000293:Adolescent; D000951:Antigens, Neoplasm / Q000032:analysis*; D015139:Blotting, Southern; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D016259:Genes, myc; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis*; D007124:Immunoenzyme Techniques; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D015999:Multivariate Analysis; D009447:Neuroblastoma / Q000235:genetics / Q000276:immunology*; D011379:Prognosis
chemical_list: D000951:Antigens, Neoplasm; D018960:Hyaluronan Receptors